Dementia and Alzheimer Disease

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the sleep disorders.

Neurology News Network. for the week ending April 20, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 19, 2024.

The instructor in neurology at Brigham and Women's Hospital talked about research exploring takotsubo syndrome, a heart condition often triggered by emotional or physical stressors, and its relationship with brain lesions. [WATCH TIME: 5 minutes]

Investigators found no trends in amyloid-imaging abnormality rates based on centile tertile levels for lecanemab-treated patients.

Patients treated with ALZ-801 showed improvements in cognition, reduced brain atrophy, and maintained dementia rating stages.

Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 12, 2024.

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about using a novel radiotracer to understand the movement of fluids and waste products in the brain. [WATCH TIME: 5 minutes]

Analyzing data from the H70-BCS, researchers identified around 6.2% of 70-year-olds meeting lecanemab treatment criteria, suggesting millions in Europe and the US might be eligible.

The smartphone tests accurately differentiated individuals with dementia from controls and were more sensitive to early symptoms than the Montreal Cognitive Assessment, a commonly used cognitive screening tool.

The newly cleared i-STAT TBI test can be used to help assess patients up to 24 hours after injury at patient bedside, with lab-quality results produced in 15 minutes.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on limb girdle muscular dystrophy.

Neurology News Network. for the week ending April 6, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending Aprl 5, 2024.

Ram Mukunda, chief executive officer of IGC Pharma, gave context to recently announced topline data highlighting IGC-AD1 as a potential option for Alzheimer disease agitation.

The company also submitted a request for a fast track designation specific to a subcutaneous version of lecanemab and is expected to hear back within 60 days from March 2024.

Overall, the reduction of hyperactivity of delta- and gamma-band activities in mTBI suggest the treatment may reduce deafferentation and GABA-ergic inhibitory interneuron dysfunctions.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine discussed ways to use a comprehensive approach when maintaining brain health. [WATCH TIME: 7 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis and MS mimics.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 29, 2024.

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders and multiple system atrophy.

The CLARiTI study spans across all 37 Alzheimer Disease Research Centers, collecting evidence on imaging and blood-based biomarkers to generate etiologic patient profiles of mixed dementia.

Transgender and gender-diverse patients have unique neurological considerations, but often, neurologists are unaware of the needs that are specific to this community.